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Introduction {#sec1-1}
============

The α2-adrenoceptors that are found in the central nervous system, peripheral nerve and autonomic ganglia are the target receptors of many drugs (Kosugi et al., 2010). Agonists of α2-adrenoceptor inhibit the conduction of nerve action potentials and can therefore contribute to an increase in the effects of local anesthetic agents (Kosugi et al., 2010). Dexmedetomidine, an α2 agonist for clinical anesthesia, is known to have various effects, such as anesthesia, analgesia, sedation, and vasoconstriction (Peng and Zhang, 2015). Additionally, dexmedetomidine has a potent anti-inflammatory effect (Li et al., 2017).

The use of dexketoprofen, a nonselective nonsteroidal anti-inflammatory drug (NSAID), is gradually increasing (Moore and Barden 2008; Miranda et al., 2012; Kara et al., 2014). Dexketoprofen is a preferred analgesic due to its faster onset of action and because it has fewer side effects than other NSAIDs (Moore et al., 2015; Hanna and Moon, 2018).

Rat sciatic nerve contains both sensory and motor nerve fibers, including nerve fibers with fast, medium and slow conduction velocities. The first appears as the activity of the fastest conducting fibers when a current pulse of the threshold stimulus intensity is applied to nerve. It is accepted that all the fibers are stimulated when a supramaximal stimulus is applied to the nerve (Katsuki et al., 2006). The compound action potentials (CAPs) recorded from supramaximal stimulus-induced rat sciatic nerve carry information about the activity of all the fibers forming the nerve. A change in the shape of the CAP may occur due to changes in the conduction velocity of the fibers (Gracias et al., 2011; Sousa et al., 2015).

The purpose of this study was to investigate the effects of different doses of dexmedetomidine and dexketoprofen on the conduction block of rat sciatic nerve.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

The experimental procedures were approved by the Necmettin Erbakan University on January 30, 2013 (approval No. 2013-024) and conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Konya/Turkey). Male Wistar albino rats (*n* = 24), aged 4--6 months and weighing 350 ± 50 g, were used in our study. Rats were provided with food and water *ad libitum* and were housed in a thermoneutral environment (22 ± 2°C) and relative humidity under a 12-hour light/dark cycle. Rats were randomly divided into three groups: a control group (*n* = 8), a dexmedetomidine group (*n* = 8) and a dexketoprofen group (*n* = 8).

Isolated rat sciatic nerve and experimental procedures {#sec2-2}
------------------------------------------------------

Rats were anesthetized with intraperitoneal pentobarbital (Pental Sodium 0.5 g injectable flacon, İ. E ULUGAY, Istanbul, Turkey) at 30 mg/kg. The sciatic nerve from the right hind limb of each rat was carefully isolated with a glass hook, and 5--6 cm of the nerve was removed. Nerve tissues were immediately transferred into the nerve chamber, which is a three-compartment system (nerve chamber, stimulating and recording Ag-AgCl electrodes) (Grass Model SIU5, Sequim, Washington, USA). The nerve chamber was superfused with a fresh Krebs solution (119 mM NaCl, 20 mM NaHCO~3~, 4.8 mM KCI, 1.8 mM CaCl~2~, 1.2 mM KHPO~4~, 1.2 mM MgSO~4~, and 10 mM glucose, gassed with a mixture 95% O~2~ and 5% CO~2~). The ambient temperature was maintained at 37°C with a pH of 7.4.

The CAP recordings were obtained from the sciatic nerve using a suction method, as previously described (Wijesinghe et al., 1991). Stimulations were applied to the proximal ends of the nerve trunk. Square wave pulses were delivered as supramaximal stimulations with a frequency of 1 Hz and duration of 200 µs by a stimulator (Grass Model S88, Sequim, Washington, USA) through a stimulation isolation unit (Grass Model SIU5, Sequim, Washington, USA). CAP recordings were obtained from the distal end of the nerve trunk (tibial branch) using a suction electrode. During the experiments, the testing equipment was kept in a Faraday's cage to avoid external noise. Preamplified (Grass Model CP511, Sequim, WA, USA) CAP signals were digitized at a 50-kHz sampling rate by an Analog/Digital converter (Advantech Model PCL1710, Cincinnati, OH, USA), acquired with the BiosigW data acquisition software (Bios, New Orleans, LA, USA), and saved for future analysis on a hard drive.

Dexmedetomidine and dexketoprofen were added to the nerve chamber at cumulative doses of 10^--9^ M, 10^--8^ M, 10^--7^ M, 10^--6^ M, and 10^--5^ M with a volume of 0.1 mL. To investigate the acute effects of dexmedetomidine and dexketoprofen, the CAPs were recorded for 5 and 10 minutes after each dose was administered. Dexmedetomidine (Precedex 200 µg/2 mL, Meditera, Izmir, Turkey), dexketoprofen (Arveles 50 mg/2 mL ampule, UFSA İlaç, Istanbul, Turkey), pentobarbital (Pental Sodium 0.5 g injectable flacon, İ. E ULUGAY, Istanbul, Turkey). Lower concentrations were obtained from the stock solutions that were made with distilled water. All chemicals were supplied by Sigma-Aldrich (Steinheim, Germany).

Analysis procedure {#sec2-3}
------------------

Several parameters were calculated to evaluate the effects of 10^--9^ M to 10^--5^ M doses of dexmedetomidine and dexketoprofen at 5 and 10 minutes after dosing. The analysis provided information regarding the electrophysiological changes in the sciatic nerve as a result of drug administration. Evaluation showed that on an example of a CAP recording (**[Figure 1](#F1){ref-type="fig"}**), MD (maximum depolarization) and AUC (area under the curve) are proportional to the number of stimulated nerve fibers in that nerve. Therefore, these values were calculated and are expressed as a percentage value relative to the control. MD was calculated with the changes in the rising phases of the CAP. MD was related to the fiber diameter distribution in the nerve fiber bundles and provided information about Na^+^ channel availability. Thus, these values were calculated and are expressed as percentage values relative to the control. The latency periods were calculated, with L~1~ measuring the time between the start of CAP and stimulation time and L~2~ measuring the time between the start of CAP and MD. These periods were used in the following equations (Eq {1} and Eq {2}) to calculate the conduction velocity of the fast-conducting nerve fibers (VCAP) and the conduction velocity of the slow- and medium-conducting nerve fibers (VMD), respectively (Dalkilic and Pehlivan, 2002). The distance was taken as the optimum value (Δx) of 50 mm between the stimulation electrode and the recording electrode.

![Demonstration of the measurement parameters on a sample recording of the compound action potentials.](NRR-15-929-g001){#F1}

V~CAP~ = Δx/Δt~L1~ {1}

V~MD~ = Δx/Δt~L2~ {2}

Statistical analysis {#sec2-4}
--------------------

SPSS 18.0 software package was used for the statistical analysis of the recorded data. Two-way analysis of variance was used to calculate the difference in parameters between experimental groups. Paired samples *t*-test with Bonferroni correction was used for the repeated measures to evaluate the difference between groups. A level of *P* \< 0.05 was considered statistically significant. All experimental parameters are expressed as the mean ± SEM (standard error of mean).

Results {#sec1-3}
=======

CAP records {#sec2-5}
-----------

Both dexmedetomidine and dexketoprofen significantly depressed all CAP parameters in a dose-dependent (**Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**) and reversible manner compared to those of the control group. CAP records for both drugs returned to baseline after 15 minutes. An example of CAP records from each drug group recorded from the rat sciatic nerve and using previously calculated parameters that best reflected the difference between the groups are presented in **[Figure 2](#F2){ref-type="fig"}**, with the same temporal axis as the stimulus artifacts.

###### 

Effects of different concentrations of dexmedetomidine on CAP parameters at 5 and 10 minutes

  Concentration (M)       AUC change (%)    MD change (%)       Maximum derivative change (%)   V~CAP~ (m/s)                                                           
  ----------------------- ----------------- ------------------- ------------------------------- ----------------- ----------------- ----------------- ---------------- ----------------
  Control                 100.00±0.00       100.00±0.00         100.00±0.00                     100.00±0.00       100.00±0.00       100.00±0.00       70.28±4.86       70.28±4.86
  10^--9^                 103.44±28.29      103.94±13.31        100.74±12.16                    100.22±9.55       101.34±14.44      95.64±10.86       64.64±4.60^\*^   66.00±6.26
  10^--8^                 95.82±25.17       85.42±15.33^\*^     89.54±20.49                     84.82±14.02^\*^   91.79±23.10       78.07±18.15       68.98±7.23       67.93±5.97
  10^--7^                 80.14±27.39       74.90±26.48^\*^     77.00±19.24^\*^                 72.46±27.71^\*^   74.61±21.05^\*^   64.54±28.74^\*^   66.93±4.63^\*^   62.84±4.48^\*^
  10^--6^                 62.87±25.80^\*^   55.54±26.86^\*^     57.25±24.65^\*^                 53.75±27.17^\*^   53.78±25.69^\*^   48.20±28.18^\*^   66.89±7.11       69.25±3.12
  10^--5^                 57.58±27.35^\*^   48.80±24.44^\*\$^   52.73±28.67^\*^                 49.10±29.25^\*^   49.52±29.59^\*^   43.61±29.28^\*^   66.57±7.10       64.91±6.37^\*^
                                                                                                                                                                       
  **Concentration (M)**   **V~MD~ (m/s)**   **L~1~ (ms)**       **L~2~ (ms)**                                                                                          
                                                                                                                                                                       
  **5 min**               **10 min**        **5 min**           **10 min**                      **5 min**         **10 min**                                           
                                                                                                                                                                       
  Control                 52.79±5.50        52.79±5.50          0.57±0.04                       0.57±0.04         0.76±0.07         0.76±0.07                          
  10^--9^                 48.02±2.98        48.78±4.14^\*^      0.62±0.04                       0.61±0.06         0.84±0.05         0.83±0.07                          
  10^--8^                 51.28±6.01        48.87±4.59^\*\$^    0.58±0.06                       0.59±0.05         0.79±0.09         0.83±0.08^\$^                      
  10^--7^                 48.21±2.87^\*^    45.64±2.49^\*\$^    0.60±0.04                       0.64±0.04^\*^     0.83±0.05         0.87±0.05                          
  10^--6^                 47.26±3.38^\*^    47.51±1.73^\*^      0.60±0.06                       0.58±0.03         0.85±0.06         0.84±0.03^\*^                      
  10^--5^                 46.67±5.30^\*^    45.80±5.60^\*^      0.61±0.06                       0.62±0.06         0.87±0.11^\*^     0.89±0.11^\*^                      

Data are expressed as the mean ± SEM. Sample size: 6, experiment repeats: 3. Two-way analysis of variance was used to compare parameters between experimental groups. \**P* \< 0.05 represents the significance compared to the control, and \$*P* \< 0.05 represents the significance compared to that at 5 minutes in the same drug concentration group. AUC: Area under the curve; CAP: compound action potential; L~1~: latency period 1, the time between the start of CAP and stimulation time; L2: latency period 2, the time between the start of CAP and maximum depolarization; MD: maximum depolarization; V~CAP~: conduction velocity of the fast-conducting nerve fibers; V~MD~: conduction velocity of the slow- and medium-conducting nerve fibers.

###### 

Effects of different concentrations of dexketoprofen on CAP parameters at 5 and 10 minutes

  Concentration (M)       AUC change (%)    MD change (%)        Maximum derivative change (%)   V~CAP~ (m/s)                                                             
  ----------------------- ----------------- -------------------- ------------------------------- ------------------- ----------------- ----------------- ---------------- ------------------
  Control                 100.00±0.00       100.00±0.00          100.00±0.00                     100.00±0.00         100.00±0.00       100.00±0.00       73.75±2.53       73.75±2.53
  10^--9^                 102.34±16.51      134.04±8.55^\*^      102.40±13.87                    101.24±12.37        100.33±16.03      95.78±24.77       67.66±3.84^\*^   67.66±6.75^\*^
  10^--8^                 109.74±5.32^\*^   119.78±16.32^\*\$^   95.38±17.33                     87.91±18.97         89.72±26.03       83.54±28.35       69.42±4.89^\*^   72.03±4.39^\*^
  10^--7^                 90.97±15.36       97.76±31.90          80.09±17.20^\*^                 69.68±23.28^\*\$^   74.67±22.22^\*^   65.55±27.77^\*^   68.36±2.36^\*^   70.59±3.49^\*\$^
  10^--6^                 72.24±26.37^\*^   78.58±42.95          61.06±23.81^\*^                 53.33±29.62^\*\$^   55.68±26.93^\*^   47.35±31.63^\*^   68.92±4.14^\*^   67.59±3.20^\*^
  10^--5^                 61.94±33.87^\*^   74.02±38.63^\$^      49.04±27.77^\*^                 48.70±25.67^\*^     43.03±28.22^\*^   43.35±26.90^\*^   68.09±4.23^\*^   69.30±3.71^\*^
                                                                                                                                                                          
  **Concentration (M)**   **V~MD~ (m/s)**   **L~1~ (ms)**        **L~2~ (ms)**                                                                                            
                                                                                                                                                                          
  **5 min**               **10 min**        **5 min**            **10 min**                      **5 min**           **10 min**                                           
                                                                                                                                                                          
  Control                 53.11±1.53        53.11±1.53           0.54±0.02                       0.54±0.02           0.78±0.06         0.78±0.06                          
  10^--9^                 49.25±2.75        47.98±5.39           0.59±0.03                       0.59±0.06           0.81±0.04         0.84±0.09                          
  10^--8^                 49.15±5.9         49.52±5.48           0.58±0.04^\*^                   0.55±0.03           0.82±0.111        0.82±0,10                          
  10^--7^                 48.58±2.33^\*^    49.26±2.81^\*^       0.58±0.02^\*^                   0.56±0.03^\*\$^     0.82±0.04         0.81±0.05                          
  10^--6^                 48.13±1.97^\*^    46,19±2.43^\*^       0.58±0.03^\*^                   0.59±0.03^\*^       0.83±0.03         0.87±0.04^\*^                      
  10^--5^                 46.75±2.21^\*^    46.75±2.16^\*^       0.58±0.03^\*^                   0.058±0.03^\*^      0.86±0.04^\*^     0.86±0.04^\*^                      

Data are expressed as the mean ± SEM. Sample size: 6, experiment repeats: 3. Two-way analysis of variance was used to compare parameters between experimental groups. \**P* \< 0.05 represents the significance compared to the control, and \$*P* \< 0.05 represents the significance compared to that at 5 minutes in the same drug concentration group. AUC: Area under the curve; CAP: compound action potential; L~1~: latency period 1, the time between the start of CAP and stimulation time; L~2~: latency period 2, the time between the start of CAP and maximum depolarization; MD: maximum depolarization; V~CAP~: conduction velocity of the fast-conducting nerve fibers; V~MD~: Conduction velocity of the slow- and medium-conducting nerve fibers.

![The dose-dependent effects of dexmedetomidine and dexketoprofen on the compound action potentials of the rat sciatic nerve recorded at 10 minutes.\
(A) Dexmedetomidine; (B) dexketoprofen.](NRR-15-929-g002){#F2}

MD values {#sec2-6}
---------

MD values were compared between dexmedetomidine and dexketoprofen at 5 and 10 minutes are shown in **[Figure 3](#F3){ref-type="fig"}**. The CAP peak values recorded for the dexmedetomidine group at the 10^--5^ M dose were 52.73 ± 28.67% at 5 minutes and 49.10 ± 29.25% at 10 minutes, which were both less than those recorded for the control group. In the dexketoprofen group treated with the same dose, these values were measured as 49.04 ± 27.77% and 48.70 ± 25.67% at 5 and 10 minutes, respectively. There was no significant difference in MD values that were calculated from the CAP records between the two drug groups (*P* \> 0.05).

![Percent changes in the dose-dependent MD of dexmedetomidine and dexketoprofen at 5 and 10 minutes.\
(A) At 5 minutes, (B) at 10 minutes. Sample size: 6, experiment repeats: 3, two-way analysis of variance was used to compare parameters between experimental groups. \**P* \< 0.05 represents the significance compared to the control, and \$*P* \< 0.05 represents the significance compared to that of 5 minutes). DXM: Dexmedetomidine; DXT: dexketoprofen; MD: maximum depolarization.](NRR-15-929-g003){#F3}

AUC values {#sec2-7}
----------

At the highest dose of dexmedetomidine and dexketoprofen (10^--5^ M), the AUC values that were calculated from the CAP records were decreased at 5 and 10 minutes when compared to those of the control group (**[Figure 4](#F4){ref-type="fig"}**). Compared to those of the controls, the AUC values of the dexmedetomidine group (10^--5^ M) at 10 minutes were more greatly reduced than those of the dexketoprofen group, but the difference was not statistically significant (*P* \> 0.05). For the 10^--6^ and 10^--5^ M doses, a statistically significant decrease in the AUC values was found at 5 and 10 minutes for the dexmedetomidine group, but only at 5 minutes for the dexketoprofen group, compared with those of the control group (*P* \< 0.05). The inhibitory concentration 50 (IC50) values were calculated with semilogarithmic sigmoidal dose-response curves using the decrease in AUC value (%) and potency, pD2 (--log IC50), and were found to be 7.62 ± 0.75 for dexmedetomidine and 6.96 ± 0.74 for dexketoprofen (**[Table 3](#T3){ref-type="table"}**). There were no statistically significant differences in potency (pD2) and efficacy (E~max~) values between dexmedetomidine and dexketoprofen (*P* \> 0.05).

![Percent changes in the dose-dependent AUC of dexmedetomidine and dexketoprofen at 5 and 10 minutes.\
(A) At 5 minutes; (B) at 10 minutes. Sample size: 6, experiment repeats: 3. Two-way analysis of variance was used to compare the parameters between experimental groups. \**P* \< 0.05 represents the significance compared to the control, and \$*P* \< 0.05 represents the significance compared to that at 5 minutes. AUC: Area under the curve; DXM: dexmedetomidine; DXT: dexketoprofen.](NRR-15-929-g004){#F4}

###### 

pD2 and Emax values for dexmedetomidine and dexketoprofen at 10 minutes

                    pD2 (--log\[drug\])   E~max~ (efficacy, % decrease of AUC)
  ----------------- --------------------- --------------------------------------
  Dexmedetomidine   7.62±0.75             53.7±14.7
  Dexketoprofen     6.96±0.74             60.3±14.6

Data are expressed as the mean ± SEM. AUC: Area under the curve; Emax: efficacy, maximum response of drug; pD2: potency of the drug.

Maximum derivative, conduction velocity values {#sec2-8}
----------------------------------------------

Treatment with three highest doses of both drugs (10^--7^, 10^--6^ and 10^--5^ M) caused a statistically significant (*P* \< 0.05) decrease in the maximum derivative of CAP at 5 and 10 minutes compared to those of the control group (**[Figure 5](#F5){ref-type="fig"}**). In addition, the reduction in conduction velocity value was significantly different (*P* \> 0.05) between the two drugs. In contrast, the conduction velocity of the fast-conducting fibers, the medium- and slow-conducting fibers was decreased for each drug at all doses and times (**[Figure 6](#F6){ref-type="fig"}**) compared to those of the controls.

![Percent changes in the dose-dependent maximum derivative of dexmedetomidine and dexketoprofen at 5 and 10 minutes.\
(A) At 5 minutes; (B) at 10 minutes. Sample size: 6, experiment repeats: 3. Two-way analysis of variance was used to compare parameters between experimental groups. \**P* \< 0.05 represents the significance compared to the control, and \$*P* \< 0.05 represents the significance compared to that at 5 minutes. DXM: Dexmedetomidine; DXT: dexketoprofen.](NRR-15-929-g005){#F5}

![Percent changes in the dose-dependent V~CAP~ and V~MD~ of dexmedetomidine and dexketoprofen at 5 and 10 minutes.\
(A) V~CAP~ at 5 minutes; (B) V~CAP~ at 10 minutes; (C) V~MD~ at 5 minutes; (D) V~MD~ at 10 minutes. Sample size: 6, experiment repeats: 3. Two-way analysis of variance was used to investigate the difference in parameters between experimental groups. \**P* \< 0.05 represents the significance compared to the control, and \$*P* \< 0.05 represents the significance compared to that at 5 minutes. DXM: Dexmedetomidine; DXT: dexketoprofen; V~CAP~: conduction velocity of the fast-conducting nerve fibers; V~MD~: conduction velocity of the slow- and medium-conducting nerve fibers.](NRR-15-929-g006){#F6}

Discussion {#sec1-4}
==========

A recent study reported that dexmedetomidine is used as an analgesic adjuvant in peripheral nerve block with an inflammatory reaction (Bagry et al., 2008; Grosu and Lavand'homme, 2015). Peripheral nerve block is a very popular technique that is used in combination with general anesthesia for postoperative analgesia in major surgery (Li et al., 2017). A series of experimental animal studies have shown the anti-inflammatory effects of peripheral nerve blocks after major surgery (Combettes et al., 2010; He et al., 2015).

In our study, the effects of the α2 agonist dexmedetomidine and the NSAID dexketoprofen, both of which are used for pain control and have an anti-inflammatory effect, on peripheral nerve conduction were examined. Results from this study showed that dexmedetomidine and dexketoprofen caused a dose-dependent suppression of all CAP parameters. The suppressed CAPs returned to baseline 15 minutes after washing. In our study, the effects of dexmedetomidine and dexketoprofen on the sciatic nerve were investigated only *in vitro*. If further studies are performed *in vivo*, the effects of dexmedetomidine and dexketoprofen on all systems can be examined or their effects on other peripheral or central nerves can be examined to provide more information about use of dexmedetomidine and dexketoprofen in pain management.

The peak values (MDs) of CAP curves decrease with an increase in dexmedetomidine dose, and as a result, AUC was decreased. The changes of MDs of CAP curves were significant at high doses (10^--6^ and 10^--5^) were significant. Oda et al. (2007) reported that dexmedetomidine inhibited voltage-dependent Na^+^ channels. Additionally, in a study using a patch-clamp method on cardiac cells, dexmedetomidine blocked the persistent sodium current induced by veratridine (Stoetzer et al., 2016). Another study reported that in frog sciatic nerve, high doses of dexmedetomidine (5 × 10^--4^ M) reduced the value of MD, but this effect might not be related to adrenoceptors (Kosugi et al., 2010). In our study, reduction of MD may be the result of inhibition of sodium channels that are active in the rising phases of CAPs.

The suppression of fast-conducting fibers causes an increase in L1 values, while the suppression of slow-conducting fibers causes an increase in L2 values (Dalkilic and Pehlivan, 2002). In the dexmedetomidine group, both latency periods increased, and consequent conduction velocity decreased compared to those of the controls. At the doses of 10^--6^ and 10^--5^ M, there were significant differences in L2 parameters between two drug groups and the control group (*P* \< 0.05). In this study, dexmedetomidine showed dose-dependent activity on slow-conducting fibers. At high doses (10^--7^, 10^--6^ and 10^--5^ M) of dexmedetomidine, a significant reduction in the maximum derivative was observed when compared to the controls. The maximum derivative is related to the maximum rate of change in the rising phase of the CAP over time and gives information about Na^+^ channels (Katsuki et al., 2006). Additionally, fast-conducting fibers make a greater contribution during the CAP rising phase. For this reason, the changes in the maximum derivatives can be interpreted as changes in the fast-conducting fibers (Dalkilic et al., 2009). Therefore, dexmedetomidine at high doses suppresses the fast-conducting fibers in the rat sciatic nerve. These results show similarities to previous studies. Butterworth and Strichartz (1993) reported that clonidine, an α2 agonist that is similar to dexmedetomidine, inhibited CAP amplitude, and this inhibition was reported to act on Aα and C fibers. According to the changes in the maximum derivative that we observed in our study, dexmedetomidine at high doses produced suppression in the fast-conducting fibers, and therefore, type A fibers could be affected.

Dexmedetomidine is used in combination with a local anesthetic to increase the amount of time that peripheral nerve conduction is blocked (Brummett et al., 2011). A meta-analysis of neuraxial adjuvant anesthesia and analgesia indicates that dexmedetomidine is a good adjuvant for local anesthesia, causing the extension of the duration of postoperative pain relief and lowering pain intensity (Wu et al., 2014). Another meta-analysis regarding the faciliatory effects of perineural dexmedetomidine reported that dexmedetomidine speeds up the sensory and motor nerve blockage, and sensory nerve blockage time was significantly extended compared to that of a placebo (Abdallah and Brull, 2013). This effect is attributed in the literature to the delayed absorption of the local anesthetic due to the local vasoconstriction caused by dexmedetomidine (Yabuki et al., 2014). The results of our *in vitro* study suggest that dexmedetomidine directly inhibits neuronal conduction.

According to the AUC analysis in our study, dexmedetomidine and dexketoprofen have similar effects on the CAP parameters recorded from rat sciatic nerve, but dexketoprofen primarily suppresses slow-fiber conduction. At low doses (10^--9^ and 10^--8^ M) of dexketoprofen, the change of AUC (%) was significantly increased at 10 minutes compared to those of the controls. This increase is explained as follows. The constant CAP amplitude (peak value, MD) during the expansion falling phase causes an increase in the AUC. However, a significant inhibition (55.90 ± 30.57%) was observed at the lowest dose (10^--9^ M) compared to that at the highest dose (10^--5^ M), resulting in the dose-dependent suppression of the conduction velocity for all fiber types distributed in the nerve bundle. Mazario et al. (1999), in a study involving rats, found that dexketoprofen inhibited single motor unit (SMU) records, which showed electrical and mechanical stimulation even at a very low dose (25 nmol/kg).

Most dexketoprofen studies to date have investigated the analgesic potency of dexketoprofen, its use in combination with other drugs, the usefulness of preemptive or postoperative administration, its use in the management of chronic pain, and its effectiveness for reducing opioid drug consumption (Yucel et al., 2013; Kelsaka et al., 2014; Kaye et al., 2018), as well as the effects on the SMU records generated by electrical or mechanical stimulation (Mazario et al., 2001; Gaitan and Herrero, 2002). However, most of the studies were conducted *in vivo*, and our study was the first to report the effect of dexketoprofen on rat sciatic nerve *in vitro*.

In this study on sciatic nerve, we observed no significant difference between dexmedetomidine and dexketoprofen in terms of inhibiting nerve conduction. However, we report that dexmedetomidine at higher doses suppresses the conduction of fast-conducting fibers, whereas dexketoprofen has a time-dependent effect on slow-conducting fibers and a dose-dependent effect on medium- and fast-conducting fibers.

**Conflicts of interest:** *The authors have no conflict of interest to declare.*

**Financial support:** *This study was supported by the Scientific Committee Foundation (No. 13102007) of Selçuk University, Konya, Turkey (to HB).*

**Institutional review board statement:** *The experimental procedures were approved by the Necmettin Erbakan University on January 30, 2013 (approval No. 2013-024).*

**Copyright license agreement:** *The Copyright License Agreement has been signed by all authors before publication.*

**Data sharing statement:** *Datasets analyzed during the current study are available from the corresponding author on reasonable request.*

**Plagiarism check:** *Checked twice by iThenticate.*

**Peer review:** *Externally peer reviewed.*

**Open peer reviewers:** *Alonzo D Cook, Brigham Young Unversity, USA; Lorenzo Di Cesare Mannelli, University of Florence, Italy.*

***Funding:*** *This study was supported by Scientific Committee Foundation (No. 13102007) of Selçuk University, Konya, Turkey (to HB).*

P-reviewers: Cook AD, Di Cesare Mannelli L; C-Editor: Zhao M; S-Editor: Li CH; L-Editor: Song LP; T-Editor: Jia Y

[^1]: **Author contributions:** *Concept and design of study, definition of intellectual content, literature retrieval, data analysis, statistical analysis, manuscript preparation and editing: SBT, HB; experimental studies and data acquisition: SBT; manuscript review: SBT. Both authors approved the final version of this paper.*
